AbbVie EBITDA Margin 2010-2023 | ABBV

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for AbbVie (ABBV) over the last 10 years. The current EBITDA margin for AbbVie as of December 31, 2023 is .
AbbVie EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2023-12-31 $54.32B $21.46B 39.50%
2023-09-30 $55.14B $23.84B 43.24%
2023-06-30 $56.02B $26.14B 46.65%
2023-03-31 $56.74B $24.71B 43.55%
2022-12-31 $58.05B $26.58B 45.79%
2022-09-30 $57.82B $25.98B 44.93%
2022-06-30 $57.35B $25.60B 44.64%
2022-03-31 $56.73B $26.90B 47.42%
2021-12-31 $56.20B $26.45B 47.06%
2021-09-30 $55.17B $25.21B 45.70%
2021-06-30 $53.73B $24.32B 45.27%
2021-03-31 $50.20B $19.99B 39.82%
2020-12-31 $45.80B $17.83B 38.94%
2020-09-30 $40.65B $16.48B 40.54%
2020-06-30 $36.23B $14.05B 38.79%
2020-03-31 $34.06B $15.65B 45.95%
2019-12-31 $33.27B $15.00B 45.09%
2019-09-30 $32.87B $8.54B 25.97%
2019-06-30 $32.62B $9.01B 27.62%
2019-03-31 $32.65B $8.31B 25.46%
2018-12-31 $32.75B $8.15B 24.88%
2018-09-30 $32.19B $12.30B 38.21%
2018-06-30 $30.95B $11.78B 38.06%
2018-03-31 $29.61B $11.61B 39.22%
2017-12-31 $28.22B $11.05B 39.15%
2017-09-30 $27.27B $11.54B 42.30%
2017-06-30 $26.71B $11.13B 41.67%
2017-03-31 $26.22B $10.76B 41.06%
2016-12-31 $25.64B $10.53B 41.07%
2016-09-30 $25.24B $10.26B 40.65%
2016-06-30 $24.75B $9.71B 39.22%
2016-03-31 $23.78B $9.07B 38.16%
2015-12-31 $22.86B $8.37B 36.63%
2015-09-30 $21.91B $5.78B 26.37%
2015-06-30 $20.99B $4.82B 22.95%
2015-03-31 $20.44B $4.49B 21.98%
2014-12-31 $19.96B $4.20B 21.03%
2014-09-30 $19.62B $6.15B 31.37%
2014-06-30 $19.26B $6.61B 34.31%
2014-03-31 $19.02B $6.58B 34.58%
2013-12-31 $18.79B $6.56B 34.92%
2013-09-30 $18.89B $6.96B 36.83%
2013-06-30 $18.74B $7.17B 38.29%
2013-03-31 $18.54B $7.20B 38.85%
2012-12-31 $18.38B $6.97B 37.91%
2012-09-30 $18.04B $-0.73B -4.02%
2012-06-30 $17.94B $2.18B 12.13%
2012-03-31 $17.72B $5.05B 28.50%
2011-12-31 $17.44B $4.89B 28.05%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $294.653B $54.318B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $690.114B 114.92
Novo Nordisk (NVO) Denmark $550.665B 45.36
Johnson & Johnson (JNJ) United States $356.431B 14.14
Merck (MRK) United States $318.604B 83.85
AstraZeneca (AZN) United Kingdom $212.533B 18.83
Novartis AG (NVS) Switzerland $200.005B 13.86
Pfizer (PFE) United States $147.226B 14.21
Sanofi (SNY) $117.121B 10.55
Innoviva (INVA) United States $0.945B 6.67